Publications - Page 35 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Pneumopathies interstitielles diffuses (PID)
Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.

Puéchal X, Iudici M, Perrodeau E, Bonnotte B, Lifermann F, Le Gallou T, Karras A, Blanchard-Delaunay C, Quéméneur T, Aouba A, Aumaître O, Cottin V, Hamidou M, Ruivard M, Cohen P, Mouthon L, Guillevin L, Ravaud P, Porcher R, Terrier B; French Vasculitis Study Group.

JAMA Netw Open. 2022 Nov 1;5(11):e2243799.
Pneumopathies interstitielles diffuses (PID)
Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease.

Héluain V, Prévot G, Cabarrou B, Calvayrac O, Taranchon-Clermont E, Didier A, Tabourier-Gouin S, Milia J, Mazières J.

Respir Med Res. 2022 Nov 30;83:100946.
Pneumopathies interstitielles diffuses (PID)
Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?

Cottin V, Brown KK, Flaherty KR, Wells AU.

Am J Respir Crit Care Med. 2022 Nov 15;206(10):1293-1294.
Pneumopathies interstitielles diffuses (PID)
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.

Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, Denton CP, Wuyts WA, Miede C, Alves M, Sambevski S, Allanore Y.

Rheumatology (Oxford). 2022 Nov 2;61(11):4397-4408.
Pneumopathies interstitielles diffuses (PID)
Diagnosis Yield and Safety of Surgical Biopsy in Interstitial Lung Diseases: A Prospective Study.

Radu D, Freynet O, Kambouchner M, Boubaya M, Nunes H, Uzunhan Y, Brillet PY, Guiraudet P, Noorah MZ, Israël-Biet D, Le Pimpec-Barthes F, Juvin K, Charpentier A, Gibault L, Assouad J, Naccache JM, Antoine M, Tavolaro S, Alifano M, Honoré I, L'Huillier JP, Debrosse D, Dupin C, Pradère P, Debray MP, Cazes A, Mordant P, Castier Y, Beloucif S, Crestani B, Lévy V, Martinod E, Valeyre D.

Ann Thorac Surg. 2022 Nov;114(5):1911-1917.
Pneumopathies interstitielles diffuses (PID)
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.

Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, James A, Kohlbrenner V, Alves M, Khanna D, Highland KB; SENSCIS-ON trial investigators.

Ann Rheum Dis. 2022 Dec;81(12):1722-1729.
Pneumopathies interstitielles diffuses (PID)
Progressive pulmonary fibrosis: an expert group consensus statement.

Rajan SK, Cottin V, Dhar R, Danoff S, Flaherty KR, Brown KK, Mohan A, Renzoni E, Mohan M, Udwadia Z, Shenoy P, Currow D, Devraj A, Jankharia B, Kulshrestha R, Jones S, Ravaglia C, Quadrelli S, Iyer R, Dhooria S, Kolb M, Wells AU.

Eur Respir J. 2022 Dec 14:2103187.
Pneumopathies interstitielles diffuses (PID)
Pleuroparenchymal fibroelastosis: so many unmet needs.

Bonniaud P, Cottin V, Beltramo G.

Eur Respir J. 2022 Dec 22;60(6):2201798.
Pneumopathies interstitielles diffuses (PID)
Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease.

Bay P, de Chambrun MP, Rothstein V, Mahevas M, De Prost N, Roux A, Zuber B, Biet DI, Hervier B, Tazi A, Mouthon L, Mekinian A, Deligny C, Borie R, Meurice JC, Meyer A, Priou P, Savale L, De Saint Martin L, Gallay L, Cottin V, Blanchard E, Brillet PY, Khafagy P, Benveniste O, Nunes H, Allenbach Y, Uzunhan Y.

J Autoimmun. 2022 Dec;133:102941.
Pneumopathies interstitielles diffuses (PID)
Lung cancer in pulmonary fibrosis: no room for nihilism!

Crestani B, Kolb M.

Eur Respir J. 2022 Dec 15;60(6):2201946.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.

Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease.

Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?

Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.

Diagnosis Yield and Safety of Surgical Biopsy in Interstitial Lung Diseases: A Prospective Study.

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.

Progressive pulmonary fibrosis: an expert group consensus statement.

Pleuroparenchymal fibroelastosis: so many unmet needs.

Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease.

Lung cancer in pulmonary fibrosis: no room for nihilism!